Share
Print

Call updates:
25 June 2015 12:20
The Flash Call Info can be found under Call Documents tab
30 March 2015 15:22
The number of proposals submitted for this topic: NMP-06-2014: 76
Flash Call Info can be found under [call documents] tab
16 December 2014 07:53
An overview of the evaluation results (flash call info) is now available under the tab ‘Call documents’.
22 October 2014 15:55 The submission session is now available for: NMP-06-2015(RIA)
After the update to the Horizon 2020 Work Programme of 22 July 2014,
the following updates were made to the topics of this call:
27 May 2014 11:37
The Work Programme for Leadership in Enabling and Industrial Technologies,
“Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing”
has been revised on 29 April 2014.
See the revised Work Programme in “Call documents” or click here.
23 May 2014 13:54
Important message on the Budget for the proposal :
In the administrative forms (Part A of the proposal) – Form "3. Budget for the Proposal" :
Column K (Requested grant) is NOT filled in automatically with the value of column J (Max. grant).
For first stage proposals, coordinators should indicate the total amount requested by the consortium, in column K.
02 May 2014 09:14
Clarification for NMP+B project proposers and evaluators on “Business Plan” and “Synergies with ESIF” - See "Call Documents"
02 April 2014 11:00
Important message on the Budget for the proposal :
In the administrative forms (Part A of the proposal) – Form "3. Budget for the Proposal" :
Column K (Requested grant) is NOT filled in automatically with the value of column J (Max. grant).
For first stage proposals, coordinators should indicate the total amount requested by the consortium, in column K.
02 April 2014 10:58
Important message on the Budget for the proposal :
In the administrative forms (Part A of the proposal) – Form "3. Budget for the Proposal" :
Column K (Requested grant) is NOT filled in automatically with the value of column J (Max. grant).
Coordinators should indicate the grant requested by each participant in Column (K).
12 March 2014 12:28
Please note that for this call, consortium partners are not required to be identified in the administrative form but must be mentioned in the Technical Annex. At a later stage, if and when invited for submitting an updated proposal under stage two, all consortium partners will have to be added in the administrative form.
10 March 2014 11:20
Clarification for NMP+B project proposers and evaluators on “Business Plan” and “Synergies with ESIF” - See "Additional Documents"
| Topic identifier: | NMP-06-2015 | ||
| Publication date: | 11 December 2013 | ||
| Types of action: | RIA Research and Innovation action | ||
| DeadlineModel: Opening date: |
single-stage 22 October 2014 |
Deadline: | 26 March 2015 17:00:00 |
| Time Zone : (Brussels time) | |||
Specific challenge: Encapsulation technologies have been widely used for a long time in the pharmaceutical industry for drug delivery applications. The emergence of nanotechnology and the availability of novel tools have paved the way for a new type of nanomatrices and nanocapsules, which can be used for targeted delivery and can carry payloads for localised action in many application fields.
Scope: Proposals should address applications for safe, controlled and reliable novel nanomatrices and nanocapsules containing active ingredients (e.g. drugs in nanomedicine, vitamins or anti-oxidants for cosmetic and personal care products, or cleaning and antimicrobial agents for housecleaning products), as well as their manufacturing processes. Different types of nanomatrices and nanocapsules are required, depending on the nature of the material (hydrophobic or hydrophilic) to be incorporated. Technical challenges relate to the production techniques involved (such as coacervation or phase separation) for improving the stability of the nano formulation and the active ingredients (payload) involved; development of novel mechanisms for the release of the payload (e.g. in response to changes in temperature or pH) is a further challenge. Nanomatrices or nanocapsules as carriers for targeted delivery could also be addressed. Safety considerations and contribution to standardization should be an integral part of the projects.
For this topic, proposals should include an outline of the initial exploitation and business plans, which will be developed further in the proposed project.
Activities expected to focus on Technology Readiness Level 4-5. Implemented as cross-KET activities.
The Commission considers that proposals requesting a contribution from the EU between EUR 3 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected impact:
Supply of safe, energy- and resource-efficient manufacturing systems for nanomatrices and nanocapsules, with the potential for radical improvements in therapy and/or quality of life;
Benefit the European healthcare and/or consumer sectors through novel new systems and improved collaborations between the key actors in the value chain;
Paving the way for the future commercialisation of such products, based on an analysis of the efficacy, safety and cost-benefit of products utilising nanomatrices/nanocapsules for the end-users or patients.
Identification of gaps in standards, paving the way for future pre-normative activities in the field.
Promoting safe-by-design approaches in collaboration with the EU nano-safety cluster and contributing towards the framework of EU nanosafety and regulatory strategies[1].
Type of action: Research & Innovation Actions
[1] EU Nano-safety strategy 2015-2020 and NanoReg project

Horizon 2020 - is a Framework Programme for Research and Technological Development, and is created by the European Union in order to support and encourage research in the European Research Area (ERA). This is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. The Horizon 2020 programme running from 2014 to 2020 has a €79 billion budget (a 46% increase over FP7).
It is structured around three core pillars:
Type of projects: mostly grants, no supplies, no works.
In order to see Horizon 2020 opportunities on DevelopmentAid, please click here.
Covers healthcare services, public health systems, and activities aimed at promoting physical and mental well-being.
Comprises laboratory facilities, equipment, and measurement activities used for scientific, technical, and analytical purposes.